News | December 19, 2011

Cardiovascular Societies Call for More Stringent Review Policies to Avoid Overuse of Stents

December 19, 2011 – The Maryland Chapter of the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI) reiterated their call for the state of Maryland to require rigorous internal and external review of stenting practices in hospitals in the state after an advisory group recommended a lower standard.

“Our priority is to ensure patients will receive safe, appropriate, high-quality cardiovascular care,” said Samuel D. Goldberg, M.D., FACC, president of the Maryland Chapter of the ACC. “By requiring each hospital to submit a written plan on an annual basis detailing how it will conduct regular internal and external review of its stenting practices, the state will be enacting important protections for Maryland’s patients.”

The Maryland Health Care Commission’s Technical Advisory Group recommended giving the Commission authority to regulate stent services as well as continuing evaluation of hospitals with stent programs, but the group stopped short of requiring an internal review that meets specific standards and an external peer review as an auditing mechanism.

Two high-profile stenting cases in Maryland hospitals were the result of “inadequate, voluntary, internal review,” Goldberg and SCAI President Christopher J. White, M.D., FSCAI, said in a letter to the Maryland Health Care Commission, which is considering the advisory group’s recommendation. The medical societies are recommending a two-pronged system of checks, including a well-defined internal review process combined with regular audits through external peer review.

The MDACC and SCAI letter to the commission can be found here: http://mhcc.maryland.gov/pci/comments_received/mdacc_pci.pdf

 

Related Content

Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Overlay Init